FDA seeks Lilly safety data

The Food and Drug Administration approved Eli Lilly’s new obesity pill this month, then told the company to collect more safety data on possible liver injury. (accessdata.fda.gov, cnbc.com) The pill is Foundayo, Lilly’s brand name for orforglipron, a once-daily tablet cleared on April 1, 2026 for adults with obesity or overweight plus at least one related condition, alongside diet and exercise. The Food and Drug Administration’s approval letter says Lilly must finish an ongoing trial and provide added data on drug-induced liver injury and major adverse cardiovascular events. (accessdata.fda.gov) The agency also ordered a study on delayed gastric emptying, a slowing of the stomach that can leave food sitting longer than usual, and a milk-only lactation study to measure how much drug reaches breast milk after a dose. CNBC, citing the Food and Drug Administration letter, reported those requirements on April 14. (accessdata.fda.gov, cnbc.com) These drugs mimic glucagon-like peptide-1, a hormone signal that cuts appetite, slows digestion, and helps people feel full longer. Kaiser Family Foundation said on January 16 that the same features that make glucagon-like peptide-1 drugs effective for obesity have also driven sharp spending pressure for Medicaid and employer plans. (kff.org, healthsystemtracker.org) That cost fight is now colliding with Lilly’s launch. Kaiser Family Foundation said Medicaid coverage of weight-loss drugs is optional for states, and several states have been re-evaluating obesity-drug benefits as budgets tighten after federal Medicaid cuts in the 2025 reconciliation law. (kff.org) The pressure extends to employers. Peterson-Kaiser Family Foundation Health System Tracker reported in October 2025 that 34% of non-elderly people with employer-sponsored insurance, or 36.2 million people, have a body mass index that would medically qualify them for a glucagon-like peptide-1 drug, and interviewed employers who said use was higher than expected and drug spending rose sharply. (healthsystemtracker.org) Lilly began selling Foundayo last week, according to CNBC, pitching a convenience edge over Novo Nordisk’s oral Wegovy because Foundayo can be taken without food or water restrictions. CNBC said trial results showed Foundayo cut body weight by 11% over 72 weeks, while oral Wegovy reduced weight by about 14% over 64 weeks. (cnbc.com) The label still carries a boxed warning tied to thyroid C-cell tumors seen with drugs in this class in rodents, and it says Foundayo is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The DailyMed label says the human relevance of those rodent tumor findings has not been determined. (dailymed.nlm.nih.gov) For Lilly, the next step is not another approval decision but follow-up evidence. The pill is already on the market, and the Food and Drug Administration now wants the company to show, with post-marketing data, how its safety profile looks in broader real-world use. (accessdata.fda.gov, cnbc.com)